Department of Gastroenterology, Digestive disease Institute, The Cleveland Clinic, Cleveland, OH, USA
Department of Gastroenterology, Digestive disease Institute, The Cleveland Clinic, Cleveland, OH, USA.
Gastroenterol Rep (Oxf). 2016 Aug;4(3):226-31. doi: 10.1093/gastro/gov007. Epub 2015 Feb 26.
Crohn's colitis (CC) is associated with primary sclerosing cholangitis (PSC). However the risk of colon cancer or dysplasia in CC and PSC is unclear. Our aim was to study the risk of colon neoplasia in CC in patients with and without PSC.
This is a nested, case-control cohort study of all patients diagnosed with concurrent CC and PSC, seen at the Cleveland Clinic between 1985 and 2012. Forty-three patients with both CC and PSC were compared with a random sample of 159 CC controls without PSC during the same period.
Seven (16.3%) of 43 CC patients with PSC developed colon cancer or dysplasia, compared with 22 (13.8%) of 159 controls (P = 0.98). Of seven colon neoplasia cases in the PSC group, 100% occurred proximal to the splenic flexure, compared with 50% (11/22) cases of colon neoplasia in controls occurring in the proximal colon (P = 0.001). Based on Cox regression analysis, male gender independently increased the risk of neoplasia [hazard ratio (HR) = 2.68; 95% confidence interval (CI) 1.30-5.54; P = 0.008], as did age at CC diagnosis (HR = 1.29; 95% CI 1.14-1.47; P < 0.001), while the use of azathioprine/6-mercaptopurine was protective (HR = 0.30; 95% CI 0.13-0.70; P = 0.005). The presence of PSC did not increase the risk for colon neoplasia (HR = 0.45; 95% CI 0.18-1.13; P = 0.09).
CC patients with PSC appear not to be at increased risk of developing colon neoplasia. Among patients in our cohort with colon neoplasia and concurrent PSC, the neoplasia occurred in the proximal colon in all cases.
克罗恩病(CC)与原发性硬化性胆管炎(PSC)有关。然而,CC 和 PSC 患者发生结肠癌或异型增生的风险尚不清楚。我们的目的是研究并发 CC 和 PSC 的患者中 CC 发生结肠肿瘤的风险,以及有无 PSC 的患者。
这是一项在克利夫兰诊所于 1985 年至 2012 年间确诊为并发 CC 和 PSC 的所有患者中进行的嵌套病例对照队列研究。将 43 例 CC 合并 PSC 患者与同期随机抽取的 159 例无 PSC 的 CC 对照组进行比较。
43 例 CC 合并 PSC 患者中有 7 例(16.3%)发生结肠癌或异型增生,而 159 例对照组中有 22 例(13.8%)(P=0.98)。PSC 组的 7 例结肠肿瘤病例中,100%发生在脾曲近端,而对照组中有 50%(11/22)的结肠肿瘤病例发生在近端结肠(P=0.001)。基于 Cox 回归分析,男性(危险比 [HR] = 2.68;95%置信区间 [CI] 1.30-5.54;P=0.008)和 CC 诊断时的年龄(HR = 1.29;95% CI 1.14-1.47;P<0.001)独立增加了肿瘤的风险,而使用硫唑嘌呤/6-巯基嘌呤具有保护作用(HR = 0.30;95% CI 0.13-0.70;P=0.005)。PSC 的存在并未增加结肠肿瘤的风险(HR = 0.45;95% CI 0.18-1.13;P=0.09)。
CC 合并 PSC 的患者似乎没有增加发生结肠肿瘤的风险。在我们的队列中患有结肠肿瘤和并发 PSC 的患者中,所有病例的肿瘤均发生在近端结肠。